Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 819 results for "novartis ag"

CSL Gains Flu-Vaccine Scale With Novartis Deal: Perreault

Paul Perreault, chief executive officer for CSL Behring LLC, talks about the acquisition of Novartis AG's influenza vaccination business and growth strategy. Perreault speaks with Erik Schatzker and Stephanie Ruhle on Bloomberg Television's ... Bloomberg, 10 hours ago

8 images for novartis ag

NDTV Profit, 2 weeks ago
InvestorPlace.com, 3 weeks ago
Bloomberg, 3 weeks ago
Daily News South Africa, 3 weeks ago
NDTV Profit, 3 weeks ago
NDTV Profit, 3 weeks ago
NDTV Profit, 3 weeks ago
The Malaysian Times, 4 weeks ago

Novartis Pharma AG Unloads Certain Specialty Product Rights to Merus for $29.5 Million

/PRNewswire/ - Merus Labs International Inc.("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] is pleased to announce that one of its wholly owned subsidiaries has signed a definitive agreement to acquire the rights to manufacture, market, and sell ...
 BioSpace11 hours ago Merus Labs Acquires Specialty Product Rights in Multiple Countries  Benzinga.com12 hours ago Merus Labs International acquires rights to manufacture, market specialty pharmaceutical products in multiple countries  News-Medical.Net10 hours ago Merus Labs to acquire rights to Salagen, Estraderm MX  Stockwatch12 hours ago
[x]  

Novartis Announces Positive Data on Oncology Drug Afinitor - Analyst Blog

Novartis AG NVS announced positive results from a phase III study, RADIANT-4, on its oncology drug Afinitor. The double-blind, randomized, parallel-group, placebo-controlled, multicenter study examined the efficacy and safety of Afinitor plus ...
 Zacks.com7 hours ago
EuroInvestor

BRIEF-Novartis says Afinitor extended life in some tumor patients

* Novartis international AG says Afinitor extended progression-free survival in phase iii trial in advanced gastrointestinal or lung neuroendocrine tumors Further company coverage: (Reporting By
 Reuters1 day ago BRIEF-Novartis says lung disease drug studies show positive results  Reuters UK2 days ago Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors  EuroInvestor1 day ago Studies from Novartis Pharma Provide New Data on Clinical Trials and Studies (Ultrafast quantitative MS-based method for ceritinib analysis in human...  4 Traders2 days ago
[x]  

Novartis AG (NVS) Showing Bullish Technicals With Resistance At $104.50

May 20, 2015 (Marketintelligencecenter.com via COMTEX News Network) -- Novartis AG ( NVS ) traded between $103.71 and $104.28 before closing at $103.80 Tuesday and presents some attractive trading opportunities today.
 PredictWallStreet2 days ago Potential Novartis AG (NVS) Trade Has 6.27% Downside Protection  Individual.com4 days ago

Ready to pay "reasonable" royalty to Novartis AG: Cipla to HC

Indian pharma firm Cipla today suggested to the Delhi High Court that it was ready to pay "reasonable" royalty to Switzerland-based drug major Novartis AG if it is allowed to manufacture respiratory disease drug, 'Indaflo', which could serve 66,000 ...
 Business Standard3 weeks ago
Reuters

Novartis 'biosimilar' drug blocked by U.S. appeals court

(Reuters) - A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients. A lower court judge rejected Amgen's request for an ...
 Reuters2 weeks ago Amgen to appeal rejection of bid to block Novartis biosimilar drug  Reuters1 month ago US judge rejects Amgen injunction bid against Novartis Sandoz unit  Economic Times2 months ago U.S. judge rejects Amgen bid to block 'biosimilar' Neupogen  Reuters2 months ago

GSK completes transaction with Novartis

Britain's GlaxoSmithKline PLC and Switzerland's Novartis AG have completed a three-part deal that will offer the British company's shareholders a 4 billion pound (USD 6.17 billion) windfall. Under the complex arrangement that closed today, Novartis ...
 Business Standard2 months ago

Mitteilung an die Inhaber von 7.50% p.a. JB Callable Multi Barrier Reverse Convertible (65%) auf Nestlé , Novartis, BHP Billiton

Offizielle Mitteilung Nr: 120294 Titel: ISIN: CH0227569552 Valorennummer / ISIN / Symbol 22756955 / CH0227569552 / JBXWO Die Bedingungen des oben erwähnten Produkts werden per sofort wie folgt angepasst: Spin Off: ...
 SIX Swiss Exchange1 day ago Mitteilung an die Inhaber von 7.30% p.a. JB Callable Multi Barrier Reverse Convertible (65%) auf Nestlé, Novartis, BHP Billiton  SIX Swiss Exchange1 day ago

Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for May 21, 2015

JNJ is a part of the Health Care sector, which includes companies such as Novartis AG ( NVS ) and Pfizer, Inc. ( PFE ). JNJ's current earnings per share, an indicator of a company's profitability, is $5.59. Zacks Investment Research reports JNJ's ...
 Nasdaq2 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - novartis ag
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less